For research use only · Not a therapeutic claim
The body of research.
Every compound on our shelves is studied for something specific. A tissue, an axis, a signalling pathway. Tap a region to see what researchers actually study there, and which peptides anchor that literature.
Subject 01 · idle
Tap a system to explore ↓
Research library
Every peptide. Every system it's studied in.
Cross-reference of what published research focuses on for each compound. Tap any region tag to jump to it on the anatomy explorer. Tap a peptide to open its full research notes on the product page.
- MuscleNNMT inhibitor investigated for muscle function, regeneration and insulin sensitivity downstream of raised NAD⁺ and SAM.
- CellularSmall-molecule NNMT inhibitor. Blocking nicotinamide methylation is studied for preserving the intracellular NAD⁺ salvage pool.
- MusclePaired research stack. BPC-157 for tendon and ligament repair, TB-500 for actin-cytoskeleton remodelling.
- GutBPC-157's foundational literature covers gastric-ulcer healing, IBD models and tight-junction restoration.
- SkinWound closure, angiogenesis and granulation-tissue formation in dermal injury models.
- PituitaryStudied as a GHRH analog driving pulsatile GH release from the anterior pituitary.
- MuscleGHRH-driven IGF-1 pulses studied for lean-mass accrual, recovery and protein synthesis.
- BrainDelta Sleep-Inducing Peptide. Studied for slow-wave sleep and CRH/cortisol response.
- PituitaryOriginal hypothalamic-pituitary sleep peptide. Modulates GH, LH and ACTH secretion.
- SkinCopper tripeptide studied for collagen synthesis, dermal remodelling and antioxidant activity.
- LiverBody's master antioxidant. Hepatic conjugation, detox pathways and oxidative-stress buffering.
- CellularMaster intracellular redox buffer. GSH/GSSG ratio is the canonical oxidative-stress readout.
- PituitarySelective GHS-R1a (ghrelin-receptor) agonist studied for pulsatile GH release from the anterior pituitary without raising cortisol or prolactin.
- MuscleGH secretagogue studied alongside GHRH analogs for IGF-1-mediated lean-mass and recovery research.
- GutRegenerative blend whose BPC-157 and KPV components are studied for gut-lining repair and NF-κB-mediated intestinal inflammation.
- SkinFour-peptide regenerative blend (GHK-Cu, BPC-157, TB-500, KPV). GHK-Cu anchors its collagen-synthesis and dermal-remodelling research.
- GutC-terminal α-MSH tripeptide. Anti-inflammatory effects on intestinal epithelium in IBD models.
- Skinα-MSH C-terminal tripeptide. Topical anti-inflammatory data in atopic dermatitis and psoriasis models.
- SkinNon-selective melanocortin-receptor agonist. Melanogenesis and pigmentation research.
- MuscleEnhances AMPK activation, insulin sensitivity and exercise capacity in rodent and human studies.
- CellularMitochondrial-derived peptide. AMPK signalling, insulin sensitivity and metabolic homeostasis.
- LiverCentral redox cofactor. Sirtuin activation, mitochondrial respiration and DNA-repair pathways.
- CellularMitochondrial NAD⁺ pool drives sirtuin and PARP activity. Central to ageing and bioenergetics.
- BrainMelanocortin-4 receptor agonist. Studied in central-nervous-system melanocortin signalling research.
- PancreasGLP-1 / GIP / glucagon triple agonist. Phase-2 weight and metabolic effects.
- LiverPhase-2 MASLD trial showed up to 80% liver-fat reduction at 24 weeks.
- BrainStudied as an anxiolytic without sedation. Modulates GABA signalling.
- BrainStudied for BDNF/NGF expression, attention and neuroprotection.
- PituitaryACTH(4-10) analog. Modulates HPA-axis stress response and corticotropin release.
- SkinAcetyl-octapeptide. Research on SNARE-complex interference and expression-line attenuation.
- BrainSmall trials suggest IGF-1-mediated cognitive effects in older adults and HIV cohorts.
- PituitaryStabilized GHRH analog. Clinical research on IGF-1 elevation and visceral adipose reduction.
- LiverJAMA 2014 trial reduced hepatic fat fraction in NAFLD with secondary MASLD-endpoint data.
- PancreasDual GLP-1 / GIP agonist. Glycaemic and weight effects in T2D research populations.
- LiverSYNERGY-NASH phase 2 hit MASH resolution with large MRI-PDFF reductions in hepatic steatosis.
- GutGLP-1 / GIP slows gastric emptying and modulates gut-hormone signalling.
Disclaimer
All compounds on this page are sold for laboratory research only. They are not approved for human consumption, diagnosis, treatment, cure or prevention of any condition. Anatomical visualisations are illustrative and reference the systems mentioned in published research literature.